Novoxel Ltd. is renowned for its groundbreaking technology and allocates many resources towards R&D, Intellectual Property and relentless protection of its Intellectual Property rights. Intellectual Property protection that promotes innovation is central to fulfilling Novoxel®’s mission to offer a better aesthetic dermatologic treatment experience for the benefit of patients and doctors. Accordingly, Novoxel globally employs a strong intellectual property strategy with a vast portfolio, including but not limited to patents and designs, that support, protect and promote innovation. The protection afforded by strong patents and designs allows Novoxel the readiness to publicly disclose information about its inventions. Patents & Designs The products listed on this website, either alone or in combination with other product(s), are protected by one or more of patents and/or designs. Additional patents and/or designs may be issued and/or pending in the United States or elsewhere.
|USA||US 9,402,678 B2|
|USA||US 10,327,832 B2|
|European Union||EP 2 459 092 B1|
|China||ZL 2014 8 0074496.5|
|USA||US 10,702,328 B2|
|China||ZL 2015 8 0061055.6|
Novoxel believes in firm and effective trademark protection. Thus not only patients and professional distributors, but also the public, rely upon trademarks to indicate uncompromising levels of trusted quality, high standards and safety.
Accordingly, Novoxel believes that strict trademark registration and relentless enforcing of its Intellectual Property rights are essential, not only to enable confident commercial decisions and encourage fair competition, but also to protect the health and safety of patients worldwide.
Trademarks must therefore be used properly. As such, please follow these guidelines for legally permitted use of Novoxel’s trademarks in all communications, documents and electronic messages. Third-party use of Novoxel’s trademarks requires a specific license or prior written permission from Novoxel, in particular Mezotix and Mesotix trademarks (*).
You may refer to Novoxel products and services by their associated Novoxel trademarks as long as such references are truthful, fair and not misleading, and comply with the following guidelines:
Please note that such guidelines may be modified by Novoxel from time to time at Novoxel's sole discretion.
(*) A third party, German company Ecomedic GmbH, owns an earlier German and EU trademark "mesotix". The European Union Intellectual Property Office has decided in a first instance decision that the trademark "mesotix" of Ecomedic GmbH was filed in bad faith and thus has to be cancelled from the register. The decision is not yet final, appeal proceedings are still ongoing. In Germany, parallel cancellation proceedings due to bad faith are ongoing at the German Patent and Trademark Office."
Last Updated: August 2020